http://opendata.unex.es/recurso/educacion/universidad/personal/9938b9aafc0f056575b2acaf6a38927e-pedro-dorado-hernandez
Relations
- teach:teacherOf
- ou:tienePublicacion
- ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: A case control study
- Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
- Analysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios
- Antipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
- Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms
- Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
- Association between CYP4A11 and EPHX2 genetic polymorphisms and chronic kidney disease progression in hypertensive patients
- Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
- CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
- CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans
- CYP2C9 gene and susceptibility to major depressive disorder
- CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
- CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
- CYP2D6 and the severity of suicide attempts
- CYP2D6 ethnic variability in hispanics
- CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
- CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
- CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
- CYP2D6 polymorphism and mental and personality disorders in suicide attempters
- CYP2D6 polymorphism in patients with eating disorders
- CYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
- CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
- CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
- CYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
- Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
- Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
- Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
- Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions
- Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
- Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
- Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis
- Eating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
- Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
- Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
- Erratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (Molecular Psychiatry (2013) 18 (266))
- Evaluating a newly developed pharmacogenetic array: Screening in a Spanish population
- Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
- Frequency of CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism in a Spanish Population: Linkage Disequilibrium with CYP2C9*3 Allele
- Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
- High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
- High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
- High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
- High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
- Highlights from the latest articles in CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen
- Incidence and factors associated with COVID-19 in 13 hemodialysis units
- Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
- Influence of CYP2D6 deletion, multiplication, -1584C→G, 31G→A and 2988G→A gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos
- Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico
- Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
- Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
- Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
- Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem
- Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
- Lessons from Cuba for global precision medicine: CYP2D6 genotype is not a robust predictor of CYP2D6 ultrarapid metabolism
- Liver enzyme abnormalities during antipsychotic treatment: A case report of risperidone-associated hepatotoxicity
- Losartan hydroxylation phenotype in an Ecuadorian population: Influence of CYP2C9 genetic polymorphism, habits and gender
- Low frequency of CYP2D6 poor metabolizers among schizophrenia patients
- Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
- MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers
- Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
- No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients [2]
- Pharmacogenetic Sex-Specific Effects of Methotrexate Response in Patients with Rheumatoid Arthritis
- Pharmacogenetic and pharmacogenomic treatment of rheumatoid arthritis: a review of Pharmacogenomics Knowledge Base scientific evidence
- Pharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
- Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine
- Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
- Pharmacogenomics and personality: Role of CYP2D6 and implications for psychopathology
- Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
- Prevalence of foot disorders according to chronic kidney disease stage
- Prevalence of potential drug–drug interaction risk among chronic kidney disease patients in a spanish hospital
- QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
- QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
- QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
- Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods
- Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
- Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers
- Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers
- Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers
- Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients
- Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients
- Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
- Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients
- Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
- Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
- Reproducibility over time of the urinary diclofenac/4′-OH diclofenac ratio among different CYP2C9 genotypes
- Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards
- The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions
- Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
- Use of pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6
- ou:perteneceAGrupoInvestigacion
- ou:imparteDocenciaEnArea
- ou:adscritoACentro
- ou:adscritoADepartamento
Inverse Relations
Inverse Blank Nodes
